Accunome Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 7

Accunome General Information

Description

Developer of molecular diagnostic technology designed to provide diagnostic instruments and detection reagents. The company focuses on research and development of molecular diagnostic technology and provides testing reagents for the diagnosis of severe diseases such as infectious diseases, enabling clients to improve diagnostic efficiency and reduce costs.

Contact Information

Website
www.accunome.com.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 601-3, Building 2, Kechuang Park, Xiuzhou National High-tech Zone
  • No. 1288, Kanghe Road
  • Jiaxing, Zhejiang
  • China
+86 0573
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Room 601-3, Building 2, Kechuang Park, Xiuzhou National High-tech Zone
  • No. 1288, Kanghe Road
  • Jiaxing, Zhejiang
  • China
+86 0573

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accunome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 14-Dec-2022 Completed Generating Revenue
4. Early Stage VC (Series A3) 03-Jun-2021 Completed Generating Revenue
3. Early Stage VC (Series A2) 10-Feb-2021 Completed Generating Revenue
2. Early Stage VC (Series A1) 31-Mar-2020 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Oct-2018 Completed Startup
To view Accunome’s complete valuation and funding history, request access »

Accunome Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Accunome Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4029929-A1 Instrument and method for extracting and detecting nucleic acids Pending 10-Sep-2019
EP-4029929-A4 Instrument and method for extracting and detecting nucleic acids Pending 10-Sep-2019
US-12618103-B2 Instrument and method for extracting and detecting nucleic acids Active 10-Sep-2019
US-20220333180-A1 Instrument and method for extracting and detecting nucleic acids Active 10-Sep-2019
WO-2021047499-A1 Instrument and method for extracting and detecting nucleic acids Inactive 10-Sep-2019 C12Q1/6851
To view Accunome’s complete patent history, request access »

Accunome Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioMérieux Corporation Minority
Ennovation Ventures Venture Capital Minority
China Merchants Fund Asset Manager Minority
Sinovation Ventures Venture Capital Minority
ZhenFund Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Accunome FAQs

  • When was Accunome founded?

    Accunome was founded in 2018.

  • Where is Accunome headquartered?

    Accunome is headquartered in Jiaxing, China.

  • What industry is Accunome in?

    Accunome’s primary industry is Laboratory Services (Healthcare).

  • Is Accunome a private or public company?

    Accunome is a Private company.

  • What is Accunome’s current revenue?

    The current revenue for Accunome is .

  • How much funding has Accunome raised over time?

    Accunome has raised $15.5M.

  • Who are Accunome’s investors?

    BioMérieux, Ennovation Ventures, China Merchants Fund, Sinovation Ventures, and ZhenFund are 5 of 7 investors who have invested in Accunome.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process